Drugmaker Eli Lilly and Company has quietly settled hundreds of personal injury lawsuits involving patients who claim they experienced withdrawal symptoms while quitting Cymbalta.
When asked for an update on the cases, Robin McCall, media relations director for Baum, Hedlund, Aristei & Goldman, P.C., one of the firms handling the cases, wrote in an email, “All we can say is that the suit has been resolved.”
Lilly is also tight-lipped about the settlement, but provided the following written statement:
“Eli Lilly and Company has reached a comprehensive resolution of all personal injury lawsuits alleging symptoms from discontinuing Lilly’s medication, Cymbalta. Lilly has defended these cases vigorously and has won every case to reach a decision on the merits, including defense verdicts in every trial. To avoid continued legal costs, Lilly reached a resolution with plaintiffs in the remaining cases. Lilly remains committed to Cymbalta and its safety and benefits, which have been repeatedly affirmed by the U.S. Food and Drug Administration.”
No additional details on the settlement were provided.
More
When asked for an update on the cases, Robin McCall, media relations director for Baum, Hedlund, Aristei & Goldman, P.C., one of the firms handling the cases, wrote in an email, “All we can say is that the suit has been resolved.”
Lilly is also tight-lipped about the settlement, but provided the following written statement:
“Eli Lilly and Company has reached a comprehensive resolution of all personal injury lawsuits alleging symptoms from discontinuing Lilly’s medication, Cymbalta. Lilly has defended these cases vigorously and has won every case to reach a decision on the merits, including defense verdicts in every trial. To avoid continued legal costs, Lilly reached a resolution with plaintiffs in the remaining cases. Lilly remains committed to Cymbalta and its safety and benefits, which have been repeatedly affirmed by the U.S. Food and Drug Administration.”
No additional details on the settlement were provided.
More
0 comments so far,add yours